VNDA
HEALTHCAREVanda Pharmaceuticals Inc
$7.44+0.05 (+0.68%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving VNDA Today?
No stock-specific AI insight has been generated for VNDA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.81$9.94
$7.44
Fundamentals
Market Cap$384M
P/E Ratio—
EPS$-4.06
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-1.0%
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding60.1M
VNDA News
20 articles- Vanda Pharmaceuticals Announces Participation at May 2026 Investor ConferencesBioSpace·May 8, 2026
- Vanda Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 7, 2026
- Vanda Pharmaceuticals Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Vanda (VNDA) Q1 2026 Earnings Call TranscriptMotley Fool·May 6, 2026
- Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 6, 2026
- Vanda Pharmaceuticals Reports First Quarter 2026 Financial ResultsYahoo Finance·May 6, 2026
- Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should KnowYahoo Finance·May 5, 2026
- Model N Appoints Thomas Gibbs to Board of DirectorsYahoo Finance·May 5, 2026
- Sector Update: Health Care Stocks Softer in Afternoon TradingYahoo Finance·May 4, 2026
- Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 YearsYahoo Finance·May 4, 2026
- Vanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026Yahoo Finance·Apr 29, 2026
- Vanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM EvidenceYahoo Finance·Apr 28, 2026
- Incyte (INCY) Beats Q1 Earnings and Revenue EstimatesYahoo Finance·Apr 28, 2026
- Geron Corporation (GERN) Appoints Timothy Williams as EVP, Chief Legal OfficerYahoo Finance·Apr 25, 2026
- Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of DirectorsYahoo Finance·Apr 22, 2026
- Sector Update: Health Care Stocks Mixed Late AfternoonYahoo Finance·Apr 9, 2026
- Sector Update: Health Care Stocks Advance in Afternoon TradingYahoo Finance·Apr 9, 2026
- Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review TimelinesYahoo Finance·Apr 9, 2026
- Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor AgonistsYahoo Finance·Apr 8, 2026
- AnaptysBio Board Approves Spin-Off of First Tracks Bio, Repurchase of $100 Million SharesYahoo Finance·Mar 27, 2026
All 20 articles loaded
Price Data
Open$7.50
Previous Close$7.39
Day High$7.74
Day Low$7.38
52 Week High$9.94
52 Week Low$3.81
52-Week Range
$3.81$9.94
$7.44
Fundamentals
Market Cap$384M
P/E Ratio—
EPS$-4.06
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin-1.0%
Debt / Equity—
Trading
Volume1.7M
Avg Volume (10D)—
Shares Outstanding60.1M
About Vanda Pharmaceuticals Inc
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—